26th Jul 2018 13:49
LONDON (Alliance News) - Destiny Pharma PLC said Thursday that it received positive data from the Phase I of its XF-73 skin irritation study.
The clinical stage biotechnology company said the study examined whether its anti-microbial active drug could cause skin irritation.
XF-73 is Destiny's lead candidate for the prevention of post-surgical staphylococcal infections, the company explained.
"We are pleased to successfully complete this Phase 1 study, confirming the safe profile demonstrated to date in all other XF-73 clinical studies," Chief Executive Officer Neil Clark said.
Destiny Pharma shares were trading up 1.8% at 111.00 pence each.
Related Shares:
DEST.L